Press "Enter" to skip to content

U.S. appeals court declines J&J bid to stop generic Zytiga sales

J&J is seeking to undo a lower court ruling from October that invalidated a patent relating to Zytiga, opening the door for generic competition.

Original source:

Also Read:   AstraZeneca's Imfinzi gets FDA priority review for small cell lung cancer